Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review

Open access
Zhao, Zhe, Wang, Xinfeng, Bao, Xiu-qi, Ning, Jingwen, Shang, Meiyu, Zhang, Dan · 2021 · Cancer Immunology, Immunotherapy

Abstract

Objective To summarize the clinical characteristics and immunological and genetic features of patients who developed autoimmune polyendocrine syndrome type II (APS-2) after treatment with immune checkpoint inhibitors (ICIs).Design and methods Several databases (MEDLINE/EMBASE/Cochrane) were searched for studies published between January 2000 and February 2020 involving patients with two or more endocrine disorders after ICI therapy.Results Our final review included 22 articles comprising 23 patients (median age 56 years; 65.2% male patients). Of these patients, 60.9% received anti-programmed cell death 1 (PD-1) therapy, 17.4% received anti-programmed cell death ligand 1 (PD-L1) therapy, and 4.3% received anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monotherapy. Patients underwent a median of four treatment cycles before the onset of the primary adverse event; the median time of onset was 8.5 weeks. Endocrine organs affected by ICI administration included the thyroid gland (18/23, 78.3%), pancreatic islets (17/23, 73.9%), pituitary gland (11/23, 47.8%), and adrenal gland (2/23, 8.7%). Related autoantibodies were detected in 65.2% of patients. In patients with diabetes, glutamic acid decarboxylase antibody was closely related to the development of diabetes ketoacidosis. The human leukocyte antigen genotype was reported in 34.8% (8/23) of patients, 5 (62.5%) of which had risk genotypes.Conclusions As a serious adverse event of ICI treatment, APS-2 is presented with abrupt initiation time and rapid development. Physicians should be aware of potential endocrine disorders and continue monitoring hormone status when treating cancer patients with ICIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-020-02699-1

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 1

  1. Schmidt MB (1926) Eine biglandulare Erkrankung (Nebennieren und Schilddruse bei Morbus Addisonni). Dtsch Pathol Ges 21:212–221

Cited by

See all 34

Metadata

Authors
Zhao, Z., Wang, X., Bao, X.-Q., Ning, J., Shang, M., & Zhang, D.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Zhang, Dan
Venue
Cancer Immunology, Immunotherapy
Published
2020-11-16
Volume
70
Issue
6
Pages
1527-1540
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W3103624149
Cited by
30
References
60
Citations by year
2026: 2 · 2025: 4 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 5
FWCI
0.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Immunology Immunotherapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Sciences Foundation of China (81630097, 81773718)
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2016-I2M-3-011)
  • Chinese Academy of Medical Sciences Fundamental Research Funds for the Central Universities (2018RC350002)
  • Drug Innovation Major Project (2018ZX09711001-003-005, 2018ZX09711001-008-005, 2018ZX09711001-003-020)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
immune checkpoint inhibitors, immune-related adverse events, PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, thyroid dysfunction, pancreatic islet autoimmunity, pituitary dysfunction, adrenal insufficiency, autoantibodies, glutamic acid decarboxylase antibodies, diabetic ketoacidosis, endocrine disorders
MeSH terms
Immune Checkpoint Inhibitors, Humans, Neoplasms, Prognosis, Polyendocrinopathies, Autoimmune

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review. https://app.cochat.ai/papers/10.1007/s00262-020-02699-1
The paper
Zhao, Z., Wang, X., Bao, X.-Q., Ning, J., Shang, M., & Zhang, D. (2021). Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-020-02699-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.